Stock Markets June 22, 2026 10:50 AM

Goldman Restores Buy on Estée Lauder, Citing Tangible Turnaround Progress and Margin Upside

Broker points to new leadership, structural operating changes and cost-savings to fuel revenue and profit recovery

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
EL

Goldman Sachs has reinstated coverage of The Estée Lauder Companies with a Buy rating and a $100 price target, arguing that recent strategic moves and operational changes are supporting a return to revenue growth and sizable margin expansion. The bank forecasts mid-single-digit revenue growth and material EPS acceleration as the company realizes cost savings and benefits from improving trends in China and travel retail.

Goldman Restores Buy on Estée Lauder, Citing Tangible Turnaround Progress and Margin Upside
EL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Goldman Sachs reinstated coverage of The Estée Lauder Companies with a Buy rating and a $100 price target, citing a tangible turnaround and underappreciated recovery in sales and earnings - Sectors impacted: Consumer Discretionary, Beauty.
  • The bank expects 4.5% revenue growth in fiscal 2026 and 2027 and forecasts EPS of $2.44 in fiscal 2026 versus $1.51 the prior year, with EBITDA and EPS projected to compound at roughly 18% and 40% annually from 2025 to 2027 - Sectors impacted: Equity markets, Financial modeling for consumer stocks.
  • Operational shifts - new leadership, the "Beauty Reimagined" strategy and a One ELC operating model - alongside cost-savings plans are credited with returning the company to growth and delivering over 300 basis points of operating margin expansion year-to-date - Sectors impacted: Corporate operations, Cost management practices.

Goldman Sachs has reinstated coverage of The Estée Lauder Companies, assigning a Buy rating and setting a $100 price target based on what the firm describes as a visible recovery in both top-line momentum and operating profitability.

The brokerage highlighted several company-level shifts that it views as foundational to the improvement: a refreshed leadership team, the roll-out of a "Beauty Reimagined" strategy and consolidation under a streamlined One ELC operating model. According to Goldman, these initiatives have coincided with a return to revenue growth in fiscal 2026 after three consecutive years of declines, as well as more than 300 basis points of operating margin expansion year-to-date.

Goldman expects that this momentum can be maintained through several operational and market dynamics already evident in the firm’s reporting. The bank points to stronger innovation pipelines, improving performance in China and a less volatile travel retail channel as key drivers. It also expects the company to take share in developed markets. Goldman views the prestige beauty category overall as attractive, projecting mid-single-digit long-term industry growth.

On the modeling side, Goldman projects revenue growth of 4.5% in both fiscal 2026 and fiscal 2027. The brokerage anticipates earnings per share of $2.44 in fiscal 2026, up from $1.51 in the prior fiscal year. Over the calendar 2025-2027 period, Goldman sees EBITDA and EPS compounding at roughly 18% and 40% annually, respectively.

Regional and channel dynamics feature prominently in Goldman’s thesis. China represented 19% of fiscal 2025 sales, and the company reportedly gained share in seven of the last eight quarters in the market. Goldman called out stronger brand-level performance across MAC, Bobbi Brown, Jo Malone and Le Labo as contributors to that trend. Meanwhile, the company’s reliance on travel retail has diminished materially - exposure has fallen to about 15% of sales from a 29% peak in fiscal 2021 - which Goldman says reduces a historical source of earnings volatility. The bank expects improved conversion in Hainan and healthier Western travel retail operations to aid future growth.

Profitability improvements are central to Goldman’s view of the recovery. The firm cited an expanded Profit Recovery and Growth Plan that it believes will support roughly 450 basis points of EBIT margin expansion through fiscal 2029. Management has increased the target for annual cost savings to $1.0 billion to $1.2 billion and widened planned workforce reductions to as many as 10,000 positions, steps the bank expects to underpin margin gains.

Goldman did not ignore downside scenarios. The brokerage explicitly noted risks that could impede the recovery, including slower-than-expected market share gains, weaker consumer demand, geopolitical disruption in the Middle East and execution challenges tied to the transformation program. Despite those risks, Goldman judged the stock’s valuation to be appealing relative to historical norms and concluded that current pricing does not fully reflect the company’s improving trajectory on growth and margins.


Implications for markets and sectors - The brokerage’s note touches on several areas of market impact: consumer discretionary and luxury/beauty sectors as direct beneficiaries of share gains and category growth; retailers and travel-focused retail operations as channels where conversion and consumer flows influence results; and cost-structure improvements that affect corporate profitability metrics more broadly.

Risks

  • Slower-than-expected market-share gains could undermine the projected revenue and margin recovery - Affects: Beauty category and consumer discretionary equities.
  • Weaker consumer demand or geopolitical disruption (e.g., in the Middle East) could impact sales and travel retail activity, weighing on earnings volatility - Affects: Travel retail channels and global luxury/beauty sales.
  • Execution challenges tied to the company’s transformation and cost-cutting program, including workforce reductions, could impede targeted savings and margin expansion - Affects: Corporate governance and operational performance.

More from Stock Markets

SpaceX Signs Potential $6.3 Billion Compute Agreement with Reflection AI Jun 22, 2026 Spanish Stocks Close Higher as IBEX 35 Hits Record; Construction, Financials and Energy-related Names Lead Jun 22, 2026 London Stocks Finish Higher as Banking and Insurance Names Lead Gains Jun 22, 2026 FDA Issues Complete Response Letter for Achieve Life Sciences’ Cytisinicline, Citing Manufacturing and Labeling Issues Jun 22, 2026 Warsaw benchmark slips as banks, tech and chemicals weigh on market Jun 22, 2026